A Novel Inflammatory and Nutritional Prognostic Scoring System for Nonpathological Complete Response Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Table 1

Clinical and pathological characteristics divided by OS-INPS.

Variables
		Age (median (IQR))	49.00(42.00-57.00)		49.00(42.00-57.00)	47.00 (42.75-56.25)	0.507
Age				0.392
≤ 49	132 (53.0)	99 (51.3)	33 (58.9)
> 49	117 (47.0)	94 (48.7)	23 (41.1)
Position				1
Left	140 (56.2)	109 (56.5)	31 (55.4)
Right	109 (43.8)	84 (43.5)	25 (44.6)
Menopause				0.083
No	137 (55.0)	100 (51.8)	37 (66.1)
Yes	112 (45.0)	93 (48.2)	19 (33.9)
Parturition				0.164
0	31 (12.4)	20 (10.4)	11 (19.6)
1	156 (62.7)	125 (64.8)	31 (55.4)
≥ 2	62 (24.9)	48 (24.9)	14 (25.0)
Clinical T stage				0.019
1	22 (8.8)	16 (8.3)	6 (10.7)
2	175 (70.3)	143 (74.1)	32 (57.1)
3	48 (19.3)	33 (17.1)	15 (26.8)
4	4 (1.6)	1 (0.5)	3 (5.4)
Clinical N stage				0.815
0	8 (3.2)	6 (3.1)	2 (3.6)
1	28 (11.2)	22 (11.4)	6 (10.7)
2	153 (61.4)	116 (60.1)	37 (66.1)
3	60 (24.1)	49 (25.4)	11 (19.6)
Clinical TNM stage				0.752
II	32 (12.9)	26 (13.5)	6 (10.7)
III	217 (87.1)	167 (86.5)	50 (89.3)
Molecular subtype				0.302
Luminal A	39 (15.7)	33 (17.1)	6 (10.7)
Luminal B	117 (47.0)	86 (44.6)	31 (55.4)
HER-2 OE	50 (20.1)	42 (21.8)	8 (14.3)
TNBC	43 (17.3)	32 (16.6)	11 (19.6)
ER				0.632
Negative	98 (39.4)	78 (40.4)	20 (35.7)
Positive	151 (60.6)	115 (59.6)	36 (64.3)
PR				0.206
Negative	123 (49.4)	100 (51.8)	23 (41.1)
Positive	126 (50.6)	93 (48.2)	33 (58.9)
HER-2				0.059
Negative	99 (39.8)	80 (41.5)	19 (33.9)
Low expression	75 (30.1)	51 (26.4)	24 (42.9)
Positive	75 (30.1)	62 (32.1)	13 (23.2)
Ki-67				0.020
<20%	107 (43.0)	91 (47.2)	16 (28.6)
≥ 20%	142 (57.0)	102 (52.8)	40 (71.4)
P53				0.129
Negative	182 (73.1)	146 (75.6)	36 (64.3)
Positive	67 (26.9)	47 (24.4)	20 (35.7)
Cycle				0.808
≤ 4	148 (59.4)	116 (60.1)	32 (57.1)
>4	101 (40.6)	77 (39.9)	24 (42.9)
L (median (IQR))	1.92 (1.60-2.45)	2.15 (1.75-2.62)	1.56 (1.37-1.80)	<0.001
N (median (IQR))	3.78 (3.00-4.73)	3.42 (2.86-4.21)	5.06 (4.51-6.07)	<0.001
M (median (IQR))	0.41 (0.34-0.52)	0.39 (0.31-0.50)	0.47 (0.40-0.57)	<0.001
Hb (median (IQR))	135.0(128.30-141.00)	135.50(129.6-141.0)	130.8 (125.9-140.3)	0.111
P (median (IQR))	239(210-283)	236(209-278)	260 (212.0-300.5)	0.115
ALB (median (IQR))	45.00 (43.00-46.50)	45.00 (43.00-46.30)	45.00 (43.00-46.62)	0.386
GLOB (median (IQR))	30.00 (27.60-33.00)	30.00 (27.30-33.00)	30.00 (27.98-33.62)	0.494
BMI (median (IQR))	24.00 (21.80-26.70)	24.00 (21.70-26.60)	23.90 (21.98-27.10)	0.522
PNI (median (IQR))	55.10 (52.30-57.50)	55.50 (52.60-58.10)	53.05 (50.60-55.30)	<0.001
AGR (median (IQR))	1.48 (1.35-1.64)	1.49 (1.38-1.63)	1.47 (1.33-1.67)	0.699
NLR (median (IQR))	1.87 (1.45-2.47)	1.66 (1.37-2.03)	3.20 (2.86-3.64)	<0.001
PLR (median (IQR))	120(98-150)	112(93-135)	165(134-206)	<0.001
MLR (median (IQR))	0.20 (0.16-0.27)	0.19 (0.15-0.22)	0.30 (0.25-0.36)	<0.001
SII (median (IQR))	441 (329-630)	397.00(299-508)	813(696-1001)	<0.001
SIRI (median (IQR))	0.77 (0.51-1.14)	0.64 (0.48-0.87)	1.50 (1.20-2.08)	<0.001

Abbreviations: INPS, inflammation and nutrition prognostic score; IQR, interquartile range; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; HER-2 OE, HER-2 overexpression; L, lymphocyte; N, neutrophil; M, monocyte; Hb, hemoglobin; P, platelet; ALB, albumin; GLOB, globulin; BMI, body mass index; PNI, prognostic nutritional index; AGR, albumin-globulin ratio; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; MLR, monocyte-lymphocyte ratio; SII, systemic immune inflammation index; SIRI, system inflammation response index.